Associate Professor David Colquhoun is a clinical cardiologist who has been in private practice in Queensland for over 30 years. He’s been involved in clinical practice and research in the fields of cardiology, lipids, nutrition, diabetes, obesity, nutraceutical and psychological aspects of heart disease.
His private clinical research unit, Core Research Group, is currently active in 17 trials. A/Prof Colquhoun is the AMA spokesperson for Cardiology in Queensland and is on the Board of the National Heart Foundation of Australia (NHFA). He is a member of the Scientific Committee of the National Institute of Complementary Medicine (NICM) and Chairman of the Preventive Cardiology Council of the Cardiac Society of Australian and New Zealand (CSANZ).
A/Prof Colquhoun has held Reviewer roles with over 30 publications including The Medical Journal of Australia, European Journal of Clinical Nutrition, International Journal of Clinical Pharmacology and Therapeutics, and Circulation to name a few.
In addition to his Associate Professor of Medicine role at the University of Queensland, A/Prof Colquhoun also holds numerous other weekly tutorials with 4th-year and 3rd-year medical students and is an examiner for RACP Practice Exams at the Greenslopes Hospital. He’s also supervised a number of postgraduate students and University of Queensland 4th-year medical students.
Most notably, A/Prof Colquhoun was announced as the Cardiologist appointed to the Australia 2020 Summit to contribute to the Long-Term National Health Strategy.
Procedures & Conditions
- Cardiac Catheterisation
- Coronary Angiograms
- General Cardiology
- Geriatric Cardiology
- Acute Coronary Syndrome
- Adult Congenital Heart Defect/Disease
- Aortic Stenosis
- Aortic Valve Disease
- Arrhythmia Management
- Atrial Fibrillation
- Atrial Flutter
- Atrial Tachycardia
- Brugada Syndrome
- Cardiac Disease
- Cardiac Sarcoidosis
- Chronic Heart Failure
- Complete Heart Block
- Coronary Artery Disease
- Dilated Cardiomyopathy
- General Cardiology
- Heart Failure
- Hypertrophic Cardiomyopathy
- Ischemic Cardiomyopathy
- Mitral Regurgitation
- Mitral Valve Disease
- Preventative Cardiology
- Pulmonary Hypertension
- Resistant Hypertension
- Sick Sinus Syndrome
- Sinus Node Dysfunction
- Structural Heart Disease
- Sudden Cardiac Death
- Valvular Heart Disease
- Ventricular Ectopy
- Ventricular Tachycardia
- Wolff-Parkinsion-White Syndrome
CardiologistGreenslopes Private Hospital 1986 - Present
CardiologistThe Wesley Hospital 1986 - Present
CardiologistSunnybank Private Hospital 2018 - Present
Medical DirectorCore Research Group 1999 - Present
Associate Professor of Medicine and Clinical CardiologistUniversity of Queensland 1986 - Present
Professional Memberships and Affiliations
Fellow of the Royal Australian College of Physicians (FRACP)
1987 - Present
Fellow of the Cardiac Society of Australia and New Zealand (FCSANZ)
1984 - Present
Member of the Australian Medical Association
1993 - Present
Member of the Australian Atherosclerosis Society
1994 - Present
Member of the International Society for the Study of Fatty Acids and Lipids
2009 - Present
Member of the Australian Lifestyle Medicine Association
2009 - Present
Member of the National Institute of Complementary Medicine
Research & Publications
Associate Professor David Colquhoun has contributed his clinical knowledge and experience to a significant number of books, publications, articles, reviews, and meetings. Below are a few of his most recent contributions:
1. Essential Fatty Acids and Eicosanoids: Invited Papers from the Third International Congress. Monounsaturates and heart disease. American Oil Chemists’ Society, 1992.
2. Cardiovascular Disease: Current Perspectives on the Asian-Pacific Region. Presentations from the Asian-Pacific Congress on Lipid Risk Factor Control, Hong Kong, 1994.
3. The Clinician’s Handbook of Lipids. Chapter 3: What are the benefits of lipid intervention? Edited by Leon A Simons. ADIS International, Sydney, 1994.
4. Therapeutic Guidelines. Cardiovascular 2008, Version 5. Chapter 2, Page 39. Cardiovascular disease risk reduction.
5. Therapeutic Guidelines. Cardiovascular 2008, Version 5. Chapter 4, Page 57. Dyslipidaemia.
6. Contributor. Working Group of the Smart State Council. Queensland Government. November 2008. Queenslanders tackling chronic disease: becoming Australia’s healthiest State. http://www.smartstate.qld.gov.au/partnerships/ss_councilreports
7. Chief Author – National Heart Foundation marine n-3 fatty acid publication. 2008
8. Chief Author – National Institute of Complementary Medicine. Evidence Based Complementary Medicines in Cardiovascular Disease. 2010
1. “Effects of Fatty Acids and Lipids in Health and Disease”. C Galli, AP Simopoulos, E Tremoli, eds Karger, Basel, 1994; for the Australian Journal of Nutrition and Dietetics, the Dietitians Association of Australia.
2. Review of a submitted paper, “Frequency of treatable causes in an Australian population with coronary disease”, for publication in the Australian and New Zealand Journal of Medicine, 1997.
3. Review on manuscript for publication in the Australia and New Zealand journal of Public Health. Manuscript no.99-12-1530: The pattern of diabetes care in NSW: A five year analysis using Medicare occasions of service data, 28 February 2000.
4. Review of article “Unstable angina – a definitive role for statins in secondary prevention”, for Medical Action Communications, May 2000.
1. Hague WE, Simes J, Kirby A, Keech AC, White HD, Hunt D, Nestel PJ, Colquhoun DM, Pater H, Stewart RA, Sullivan DR, Thompson PL, West M, Glasziou PP, Tonkin AM, Lipid study Investigators. Long-term effectiveness and safety of Pravastatin in patients with coronary heart disease: sixteen years of follow-up of the LIPID study. Circulation. 2016, May. 133(19): 1860.
2. Roberts MA, BLOCADE Collaborative Study Group (Colqhoun D) et al. The ß-blocker to lower cardiovascular dialysis events (BLOCADE) feasibility study: a randomized controlled trial. AJKD 2016 June;67(6):902-911.
3. Cho L, Rocco M, Colquhoun D, Sullivan D, Rosenson RS, Dent R, Xue A, Scott R, Wasserman SM, Stroes E. Clinical Profile of Statin Intolerance in the Phase 3 GAUSS-2 Study. Cardiovasc Drugs Ther. 2016 Jun;30(3):297-304.
4. Fitzmaurice DA, Accetta G, Haas S, Kayani G, Lucas Luciardi H, Misselwitz F, Pieper K, Ten Cate H, Turpie AG, Kakkar AK, GARFIELD-AF Investigators (Colquhoun D). Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELD-AF and treated with vitamin K antagonists. Br J Haematol 2016 Aug;174(4):610-23.
5. Simons LA, Ortiz M, Freedman SB, Waterhouse BJ, Colquhoun D, Thomas G. Improved persistence with non-vitamin-K oral anticoagulants compared with warfarin in patients with atrial fibrillation: recent Australian experience. Curr Med Res Opin. 2016 Nov;32(11):1857-1861.
6. Cohen AT, Harrington RA, Goldhaber SZ, Hull RD, Wiens BL, Gold A, Hernandez AF, Gibson CM, APEX Investigators (Colqhoun D). Extended thromboprophylaxis with Betrixaban in acutely ill medical patients. N Engl J Med. 2016 Aug 11;375(6):534-44.
7. Mentz RJ, Bethel MA, Gustavson S, Thompson VP, Pagidipati NJ, Buse JB, et al. Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL), (Colquhoun – Investigator). American Heart Journal, 187, 1–9. https://doi.org/10.1016/j.ahj.2017.02.005
8. Stewart RAH, Colquhoun DM, Marschner SL, Kirby AC, Simes J, Nestel PJ, Glozier N, O’Neil A, Oldenburg B, White HD, Tonkin AM, LIPID study Investigators. Persistent psychological distress and mortality in patients with stable coronary artery disease. Heart. June 2017; 103: 1860 – 1866.
9. Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. (Colquhoun – Investigator), N Engl J Med. 2017;377(14):1319-1330.
10. Simons LA, Ortiz M, Freedman B, Waterhouse BJ, Colquhoun D. Medium to long-term persistence with non-vitamin K oral anticoagulants in patients with atrial fibrillation: Australian experience, Current Medical Research and Opinion, DOI: 10.1080/03007995.2017.1321535.
11. Corresponding Author: Andrea Driscoll. Co-Authors: Barnes E, Nestel P, Stewart R, Hunt D, Simes J, West, M, Tonkin A, White H, Colquhoun D. Predictors of incident heart failure in patients after an acute coronary syndrome: the LIPID heart failure risk-prediction model. International Journal of Cardiology N Engl J Med. 2017 Dec 1;248:361-368
12. Simes J, Robledo KP, White HD, Espinoza D, Stewart RA, Sullivan DR, Zeller T, Hague W, Nestel PJ, Glasziou PP, Keech AC, Elliott J, Blankenberg S, Tonkin AM, LIPID study Investigators. D-dimer predicts long-term cause-specific mortality, cardiovascular events and cancer in stable coronary heart disease patients: The LIPID Study, (Colquhoun – Investigator). Circulation. 2018 Aug; 138(7) 712 – 723.
13. Colquhoun D, Freedman B, Cross D, Fitzgerald, B, Forge B, Hare D, Tatoulis J, Wicks J, Wilson A, Zecchin R, Clinical Exercise Stress Testing in Adults (2014), Heart, Lung and Circulation (2015).
14. Nestel P, Clifton P, Colquhoun D, Noakes M, Mori TA, Sullivan D, Thomas B. Indications for Omega-3 Long Chain Polyunsaturated Fatty Acid in the Prevention and Treatment of Cardiovascular Disease. Heart Lung Circ. 2015 Aug;24(8):769-79
15. Tonkin AM, Blankenberg S, Kirby A, Zeller T, Colquhoun DM, Funke-Kaiser A, Hague W, Hunt D, Keech AC, Nestel P, Stewart R, Sullivan DR, Thompson PL, West M, White HD, Simes J; LIPID study investigators. Biomarkers in stable coronary heart disease, their modulation and cardiovascular risk: The LIPID biomarker study. Int J Cardiol. 2015 Dec 15;201:499-507
16. Hamilton-Craig I, Colquhoun D, Kostner K, Woodhouse S, d’Emden M. Lipid-modifying therapy in the elderly. Vasc Health Risk Manag. 2015 May 14;11:251-63
17. Lip GY, GARFIELD Investigators (Colquhoun D) et al. Does sex affect anticoagulant use for stroke prevention in nonvalvular atrial fibrillation? The prospective global anticoagulant registry in the FIELD-Atrial Fibrillation. Circ Cardiovasc Qual Outcomes. 2015 Mar;8(2 Suppl 1):S12-20.
18. Fauchier L, CLARIFY Investigators (Colquhoun D) et al. Use of anticoagulants and antiplatelet agents in stable outpatients with coronary artery disease and atrial fibrillation. International CLARIFY Registry. PLOS One 2015 April.
19. Fulcher G, Matthews DR, Perkovic V, de Zeeuw D, Mahaffey KW, Mathieu C, Woo V, Wsyham C, Capuano G, Desai M, Shaw W, Vercruysse F, Meininger G, Neal B, CANVAS trial collaborative group (Colquhoun D). Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes. Diabetes Obes Metab. 2016 Jan;18(1):82-91.
20. Cho L, Rocco M, Colquhoun D, Sullivan D, Rosenson RS, Dent R, Xue A, Scott R, Wasserman SM, Strokes E. Clinical profile of statin intolerance in the phase 3 GAUSS-2 study. Cardiovasc Drugs Ther 2016 Mar 2. Epub 2016 Mar 2.
More research publications available upon request.View More
Associate Professor David Colquhoun has been invited to a significant number of national and international speaking engagements. Below are a few of his most recent contributions:
1. Australian Lifestyle Medicine Association Annual Conference September, Sydney. Topic: The two way relationship between depression and heart disease. Topic: Alcohol and heart disease.
2. Astra Zeneca Post Graduate Weekend September Brisbane. Topic: CV treatment options for type 2 diabetic patients.
3. Novartis October Brisbane. Topic: Fasting plasma glucose and HbA1c in relation to CHD, and the appropriate use of Galvumet in type 2 diabetes.
4. GP13 Conference Royal Australian College of General Practitioners. October Darwin. Topic: National Heart Foundation of Australia Consensus Statement on Depression in patients with Coronary Heart Disease: recommendations for screening, referral and treatment. Topic: The National Heart Foundation of Australia consensus statement on psychosocial risk factors for coronary heart disease.
5. Weighty Matters GP Conference, October, Toowoomba. Topic: Lipids 2013: The roles of statins and fish oil
6. Bayer Educational Event, Toowoomba, October. Topic: Developments in oral anti-coagulation for stroke prevention in non-valvular atrial fibrillation. Topic: Appropriate prescribing and management of patients on Xarelto (Rivaroxaban)
7. Omega-3 Centre Conference Newcastle November. Topic: Omega-3 and heart health – an Australian perspective
8. Servier Education Meeting Clayfield November. Topic: Managing CV risk in our patients – what does the evidence suggest about the options we have?
9. Annual Women’s Health Update, University of New South Wales, February. Topic: Why Atrial Fibrillation is more Fatal for Women
10. MSD Education Meeting (Paddington February, Margate March) Topic: A combination strategy to help manage hyperlipidaemia.
11. School of Pharmacy, 2015 Seminar Series, UQ March. Topic: Heart disease and risk factors including diet and depression.
12. Men’s Health Seminar, Australian Doctor Education, Brisbane. Topic: What kills men and why?
13. Servier Education Dialogues in Depression Meeting, Sydney March. Topic: Heart and Mind
14. The Annual Women’s and Children’s Health Update, Adelaide May. Topic: Why Atrial Fibrillation is more Fatal for Women.
15. Bristol-Myers Squibb Education Meeting, Herston May. Topic: A case study approach to treating patients presenting with AF
16. ACEP 2015 Annual Meeting, Melbourne June. Topic: Complimentary therapies
17. The Annual Women’s and Children’s Health Update, Brisbane June. Topic: Why Atrial Fibrillation is more Fatal for Women.
18. GPH Clinical Scientific Meeting, Brisbane June. Topic: Is reading bad for you
19. The Wesley Hospital Clinical Education – Cardiology July. Topic: Quo Vadis Warfarin
20. CSANZ Annual Scientific Meeting, Melbourne August 2015. Topic:
– Do we need new lipid guidelines in Australia?
– Persistent psychological distress and mortality in patients with stable coronary artery disease in the LIPID trial.
– Women with atrial fibrillation have greater stroke rates than men on Warfarin: Narrowing the gender gap on NOACs.
– Alcoholic beverages: separating facts from fiction, avoiding prejudice and polemics and getting the dose right.
21. The Wesley Hospital Cardiology and Vascular Education Program, July. Topic: – Aspirin or NOAC?
– Is atrial fibrillation more dangerous in women?
– Alcohol – is it good or bad for your heart?
22. Thrombo 360 Experience, (Gold Coast September, Brisbane September, Melbourne October) Topic:
– Eliquis in DVT/PE and NVAF
– Workshop – GP Management – A Focus on ATRIAL FIBRILLATION
– The Eliquis Experience – Stroke Prevention in NVAF
23. QCRA-Heart Foundation Queensland – Secondary Prevention Symposium, Brisbane October. Topic: Psychosocial links to CHD
24. GP Education Evening – Hillcrest Private Hospital Rockhampton October. Topic: Cardiovascular Disease: Hot Topics plus Q&A.
25. Heart Failure Nurses’ Weekend, Brisbane October. Topic: Managing Comorbidities to Improve Patient Outcomes
26. GP Education Day – University of Queensland, October. Topic:
– Stroke Prevention
– Heart Disease
27. Reflections: Cardiology and Endocrinology Perspectives on SGLT2 inhibitor CV outcome trials. Brisbane November. Topic: A Cardiology Perspective.
28. GPH Clinical Scientific Meeting, Brisbane December. Topic: Clots aren’t clots: arterial vs venous.
29. Heart Foundation of Queensland “Boardroom Luncheon”, Brisbane December. Topic: From our heart, for all hearts
30. Heart Foundation of Queensland “Leaders in Cardiology” Brisbane December. Topic: Workshop for Leaders in Cardiology
More presentations available upon request.View More